Serological biomarkers such as carcinoembryonic antigen (CEA), cytokeratin fragment 19 (CYFRA21-1) and neuron-specific enolase (NSE), have been mainly investigated as prognostic or predictive markers in NSCLC patients treated with chemotherapy [7, 8]. This evidence concerns the gene ENO2 and non-small cell lung carcinoma.